Susie Germano

Susie Germano

Auto-generated profile, based on publicly available information

Susie Germano

Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2022 in Science Advances
Verified
Journal Article
Open access
SBSamantha Bannister
Samantha Bannister
BKBowon Kim
Bowon Kim
Jorge Dominguez‐AndresJorge Dominguez‐Andres
Jorge Dominguez‐Andres
GKGizem Kilic
Gizem Kilic
BABrendan R. E. Ansell
Brendan R. E. Ansell
BNBoris Novakovic
Boris Novakovic
Trained immunity describes the capacity of innate immune cells to develop heterologous memory in response to certain exogenous exposures. This phenomenon mediates, at least in part, the beneficial off-target effects of the BCG vaccine. Using an in vitro model of trained immunity, we show that BCG exposure induces a persistent change in active histone modifications, DNA methylation, transcription, and adenosine-to-inosine RNA modification in human monocytes. By profiling DNA methylation of circulating monocytes from infants in the MIS BAIR clinical trial, we identify a BCG-associated DNA methylation signature that persisted more than 12 months after neonatal BCG vaccination. Genes associated with this epigenetic signature are involved in viral response pathways, consistent with the reported off-target protection against viral infections in neonates, adults, and the elderly. Our findings indicate that the off-target effects of BCG in infants are accompanied by epigenetic remodeling of circulating monocytes that lasts more than 1 year.

1 January 2022 in Clinical & Translational Immunology
Verified
Journal Article
Open access
NMNicole L Messina
Nicole L Messina
SGSusie Germano
Susie Germano
RMRebecca McElroy
Rebecca McElroy
RRRajeev Rudraraju
Rajeev Rudraraju
RBRhian Bonnici
Rhian Bonnici
TTThe Brace Trial
The Brace Trial
Background and objectives: Because of its beneficial off‐target effects against non‐mycobacterial infectious diseases, bacillus Calmette–Guérin (BCG) vaccination might be an accessible early intervention to boost protection against novel pathogens. Multiple epidemiological studies and randomised controlled trials (RCTs) are investigating the protective effect of BCG against coronavirus disease 2019 (COVID‐19). Using samples from participants in a placebo‐controlled RCT aiming to determine whether BCG vaccination reduces the incidence and severity of COVID‐19, we investigated the immunomodulatory effects of BCG on in vitro immune responses to SARS‐CoV‐2.Methods: This study used peripheral blood taken from participants in the multicentre RCT and BCG vaccination to reduce the impact of COVID‐19 on healthcare workers (BRACE trial). The whole blood taken from BRACE trial participants was stimulated with γ‐irradiated SARS‐CoV‐2‐infected or mock‐infected Vero cell supernatant. Cytokine responses were measured by multiplex cytokine analysis, and single‐cell immunophenotyping was made by flow cytometry.Results: BCG vaccination, but not placebo vaccination, reduced SARS‐CoV‐2‐induced secretion of cytokines known to be associated with severe COVID‐19, including IL‐6, TNF‐α and IL‐10. In addition, BCG vaccination promoted an effector memory phenotype in both CD4+ and CD8+ T cells, and an activation of eosinophils in response to SARS‐CoV‐2.Conclusions: The immunomodulatory signature of BCG’s off‐target effects on SARS‐CoV‐2 is consistent with a protective immune response against severe COVID‐19.

27 October 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
LPLaure F Pittet
Laure F Pittet
NMNicole L Messina
Nicole L Messina
KGKaya Gardiner
Kaya Gardiner
FOFrancesca Orsini
Francesca Orsini
VAVeronica Abruzzo
Veronica Abruzzo
NCNigel Curtis
Nigel Curtis
Introduction BCG vaccination modulates immune responses to unrelated pathogens. This off-target effect could reduce the impact of emerging pathogens. As a readily available, inexpensive intervention that has a well-established safety profile, BCG is a good candidate for protecting healthcare workers (HCWs) and other vulnerable groups against COVID-19. Methods and analysis This international multicentre phase III randomised controlled trial aims to determine if BCG vaccination reduces the incidence of symptomatic and severe COVID-19 at 6 months (co-primary outcomes) compared with no BCG vaccination. We plan to randomise 10 078 HCWs from Australia, The Netherlands, Spain, the UK and Brazil in a 1:1 ratio to BCG vaccination or no BCG (control group). The participants will be followed for 1 year with questionnaires and collection of blood samples. For any episode of illness, clinical details will be collected daily, and the participant will be tested for SARS-CoV-2 infection. The secondary objectives are to determine if BCG vaccination reduces the rate, incidence, and severity of any febrile or respiratory illness (including SARS-CoV-2), as well as work absenteeism. The safety of BCG vaccination in HCWs will also be evaluated. Immunological analyses will assess changes in the immune system following vaccination, and identify factors associated with susceptibility to or protection against SARS-CoV-2 and other infections. Ethics and dissemination Ethical and governance approval will be obtained from participating sites. Results will be published in peer-reviewed open-access journals. The final cleaned and locked database will be deposited in a data sharing repository archiving system. Trial registration ClinicalTrials.gov NCT04327206

1 May 2015 in Tuberculosis
Verified
Journal Article
Closed access
VCVanessa Clifford
Vanessa Clifford
CZChristel Zufferey
Christel Zufferey
SGSusie Germano
Susie Germano
NRNorbert Ryan
Norbert Ryan
DLDavid Leslie
David Leslie
NCNigel Curtis
Nigel Curtis

1 September 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
NSNatalie Emilia Stevens
Natalie Emilia Stevens
FRFeargal Ryan
Feargal Ryan
NMNicole L. Messina
Nicole L. Messina
SBStephen J. Blake
Stephen J. Blake
TNTodd S. Norton
Todd S. Norton
DLDavid Lynn
David Lynn
No evidence of durable trained immunity after two doses of adenovirus-vectored or mRNA COVID-19 vaccines

1 August 2019 in Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Verified
Journal Article
Open access
ESEva L. Sudbury
Eva L. Sudbury
LOLarissa Otero
Larissa Otero
MTMarc Tebruegge
Marc Tebruegge
NMNicole L. Messina
Nicole L. Messina
CSCarlos Seas
Carlos Seas
NCNigel Curtis
Nigel Curtis
The tuberculin skin test and interferon-gamma release assays have limitations in diagnosing tuberculosis (TB), particularly in children. This study investigated the performance of candidate M. tuberculosis-specific cytokine biomarkers for TB in children in a TB-endemic setting. A total of 237 children with a household contact with smear-positive pulmonary TB were recruited. Importantly, a group of children with illnesses other than TB (sick controls) was included to assess specificity. Median IFN-ɣ, IL-1ra, IL-2, IL-13, IP-10, MIP-1β and TNF-α responses were significantly higher in children with active TB and latent TB infection (LTBI) than in both healthy and sick control children. Three of these cytokines - IL-2, IL-13 and IP-10 - showed better performance characteristics than IFN-ɣ, with IL-2 achieving positive and negative predictive values of 97.7% and 90.7%, respectively. Furthermore, IL-1ra and TNF-α responses differed significantly between active TB and LTBI cases, suggesting that they may be stage-specific biomarkers. Our data indicate that incorporating these biomarkers into future blood-based TB assays could result in substantial performance gains.